Skip to main content
    E

    Eli Lilly and Company (LLY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $1433.55
    -9.95 (-0.69%)

    Market Cap: $1.29T

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Eli Lilly and Company (LLY) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Eli Lilly and Company (LLY) to earn $35.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $91.67B. Of 31 analysts, 26 rate the stock Buy or Strong Buy, 3 Hold and 2 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $50.64.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 31 ratings average 2.06, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 84% of the ratings.

    RatingAnalystsShare
    Strong Buy619.4%
    Buy2064.5%
    Hold39.7%
    Sell13.2%
    Strong Sell13.2%
    Consensus
    Buy
    Total analysts
    31

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 43.1% and revenue estimates rise 16.2%.

    Fiscal year ending Dec 31, 2026
    $35.39
    EPS consensus, revenue $91.67B
    Fiscal year ending Dec 31, 2027
    $50.64
    EPS consensus, revenue $106.49B
    Next report
    Feb 2, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$35.39$32.68 to $36.2826$91.67B$88.56B to $93.00B25
    Dec 31, 2027$50.64$41.28 to $59.8128$106.49B$93.90B to $114.30B29

    Quarterly Estimates

    The EPS consensus falls from $11.28 for the quarter ending Dec 31, 2026 to $10.94 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$11.28$10.15 to $13.0421$24.84B$23.34B to $27.10B18
    Mar 31, 2027$10.94$10.31 to $11.636$23.55B$22.64B to $24.60B5

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 20 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2027181
    Quarter ending Mar 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.1% from $36.51.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$35.39$35.35$35.77$36.71$36.51-3.1%
    Fiscal year ending Dec 31, 2027$50.64$50.15$47.64$47.24$46.63+8.6%
    Quarter ending Mar 31, 2027$10.94$10.46$9.96$9.73$9.94+10.1%

    Frequently Asked Questions About LLY

    What is the LLY stock forecast?

    Consensus analyst estimates put Eli Lilly and Company's EPS at $35.39 for the fiscal year ending Dec 31, 2026, on revenue of $91.67B. The consensus rating from 31 analysts is Buy.

    How do analysts rate LLY stock?

    Of 31 analysts covering Eli Lilly and Company, 6 rate it Strong Buy, 20 Buy, 3 Hold, 1 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from LLY next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $35.39, with estimates from $32.68 to $36.28 from 26 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $50.64, with estimates from $41.28 to $59.81 from 28 analysts.

    What revenue do analysts expect from Eli Lilly and Company next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $91.67B, with estimates from $88.56B to $93.00B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $106.49B, with estimates from $93.90B to $114.30B.

    How many analysts cover LLY?

    31 analysts rate Eli Lilly and Company stock, and 26 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.